Free Trial
→ $0. Later: $29.97. (From Profits Run) (Ad)tc pixel
NASDAQ:PXMD

PaxMedica Q1 2024 Earnings Results & Report

PaxMedica logo
$0.0007 0.00 (0.00%)
As of 11/11/2026 09:30 AM Eastern

PaxMedica missed analyst earnings expectations in its Q1 2024 results, released May 13, 2024. The company reported EPS of -$0.50 versus the -$0.43 consensus estimate.

Research:Profile

Earnings Announcement Details

Quarter
Q1 2024
Report Date

PaxMedica EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

PaxMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

PaxMedica's next earnings date is estimated for Wednesday, December 2, 2026, based on past reporting schedules.

Conference Call Resources

PaxMedica Q1 2024 Earnings FAQ

PaxMedica (NASDAQ:PXMD) reported earnings of -$0.50 per share for Q1 2024, missing the consensus estimate of -$0.43. The report was announced on Monday, May 13, 2024.

PaxMedica's next earnings date is estimated for Wednesday, December 2, 2026. MarketBeat tracks confirmed and estimated earnings dates for PaxMedica on the company's earnings history page.

PaxMedica Earnings Headlines

PaxMedica, Inc. (PXMD) - Yahoo Finance
July 11, 2025  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/PXMD/
Study Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD Patients
September 23, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/study-links-iron-deficiency-to-disturbed-sleep-among-autism-adhd-patients/ar-AA1r3Lgv
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
November 13 at 1:00 AM  |  Weiss Ratings (Ad)
BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
September 3, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/biomednewsbreaks-paxmedica-inc-pxmd-announces-immediate-exercise-of-warrants-to-total-approximately-884k/ar-AA1pVZlL
Yale Study Unravels Autism, Brain Growth Patterns
September 1, 2024  |  msn.comhttps://www.msn.com/en-us/health/other/yale-study-unravels-autism-brain-growth-patterns/ar-AA1pIVO0
PaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection
August 27, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/63099646-paxmedica-inc-paxmedica-reports-first-patient-treated-with-pax-101-for-fatal-african-sleeping-sickness-infection-200.htm
See More PaxMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PaxMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PaxMedica and other key companies, straight to your email.

About PaxMedica

PaxMedica (NASDAQ:PXMD) is a clinical-stage biopharmaceutical company focused on developing treatments for neurodevelopmental disorders and other conditions with significant unmet medical needs. The company’s research has centered on therapies intended to address symptoms and underlying biological mechanisms associated with these disorders.

PaxMedica’s primary product candidate is PAX-101, an intravenous formulation of suramin, an established antiparasitic compound. The company has evaluated PAX-101 in clinical studies for autism spectrum disorder and has also explored its potential in other neurodevelopmental conditions, including Fragile X syndrome and Phelan-McDermid syndrome.

In addition to its neurodevelopmental research, PaxMedica has pursued opportunities involving suramin in infectious disease, including human African trypanosomiasis, commonly known as sleeping sickness. The company is based in the United States and has focused its development activities on advancing clinical programs rather than marketing commercially approved products. Howard J. Jaffe, M.D., has been associated with the company’s leadership.

View PaxMedica Profile
Earnings Tools